Oncology Medical News about neoadjuvant chemotherapy;interval debulking surgery;serous endometrial cancer

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Neoadjuvant chemotherapy followed by interval debulking surgery in patients with serous endometrial cancer with transperitoneal spread (stage IV): a new preferred treatment?
British Journal of Cancer, 07/02/09

Vandenput I et al. - In a study to investigate the value of neoadjuvant chemotherapy (NACT), followed by interval debulking surgery (IDS), in endometrial cancer with transperitoneal spread (stage IV), it was found that use of NACT resulted in a high rate (80%) of optimal IDS for treatment of endometrial cancer with transperitoneal spread.

Methods

Pts with endometrial cancer with transperitoneal spread, as determined by laparoscopy (±pleural effusion), were treated with NACT.
Efficacy was determined according to the Response Evaluation Criteria in Solid Tumors (RECIST), residual tumour at IDS and histopathological assessment of tumour regression.

Results

30 pts (median age: 65 yrs) received 3–4 cycles of NACT (83% paclitaxel/carboplatin).
Histopathological subtypes were as follows: serous (90%), clear cell (3%), and endometrioid (6%) carcinoma.
Response according to RECIST was as follows: 2 (7%) complete remission, 20 (67%) partial remission, 6 (20%) stable disease, and 2 (7%) progressive disease (PD).
Pts with PD were not operated upon.
24 pts (80%) had optimal cytoreduction (R 1 cm), of whom 22 (92%) were without residual tumour.
4 pts were considered inoperable and were excluded from further analysis.
Median progression-free survival (PFS) and overall survival (OS) times were 13 and 23 mos, respectively.
Histopathological features of chemoresponse in both uterus and omentum were related to better PFS and OS.
Absence of tumour infiltration and necrosis were associated with prognosis.

<< Previous
Type I collagen inhibits differentiation and promotes a stem...

Next >>
Treatment regimen extends survival for women with cervical cancer